Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Key Points GAAP revenue surged to $4.0 million in Q2 2025, beating analyst expectations by 381.9%. GAAP net loss per share improved to $(0.50) in Q2 2025, slightly better than the estimated $(0.52).

HHS says the elimination of 22 mRNA vaccine development projects for COVID-19 and bird flu signals a shift in vaccine ...

Q2 2025 Management View CEO Michael S. Exton stated, "When we entered 2025, if you recall, we're still in the early days of ...

Operating expenses decreased sharply compared to Q2 2024, supporting a cash runway into the second quarter of 2026. - Dose expansion enrollment was completed for the lead product in its main clinical ...

Researchers at the University of New Mexico are preparing to launch a phase 1 clinical trial for an Alzheimer's vaccine after ...

Pelage’s PP405, a first-in-class regenerative treatment, reactivates dormant stem cells to regrow hair. Phase 2a shows early, significant results.

Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given.

The current quarter introduced the 15% onetime stock dividend and confirmed accelerated site activation for OVATION 3, compared to the previous quarter's focus on initial site readiness and ...

A phase 3, international, randomized clinical trial assessed the safety and efficacy of canagliflozin for treatment of type 2 diabetes mellitus (T2DM) in children and adolescents.

Topical Ketamir-2 significantly reduced both acute and inflammatory pain behaviors in animals, demonstrating rapid onset, ...